Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial

RATIONALE: Abnormal glucose metabolism is a common complication in people with cystic fibrosis (CF), and those with impaired glucose tolerance (IGT) or CF-related diabetes (CFRD) have increased disease burden. Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is safe and effective for people with CF aged

• Durieu, I.
• Clements, B.
• Fabrizzi, B.
• Mall, M. A.
• McKone, E.
• Ramsey, B.
• Tullis, E.
• Taylor-Cousar, J. L.
• van der Meer, R.
• Bachman, E.
• Chin, A.
• Conner, S.
• Jennings, M.
• Weinstock, T.
• Colombo, C.
• Robinson, P.